Published in J Virol on October 01, 2001
Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med (2010) 2.62
Animal models of human respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol (2011) 1.57
NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus. J Virol (2002) 1.55
Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis (2011) 1.38
Perforin is a critical physiologic regulator of T-cell activation. Blood (2011) 1.32
Human genetic factors and respiratory syncytial virus disease severity. Clin Microbiol Rev (2008) 1.30
Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J Virol (2006) 1.28
Replication and clearance of respiratory syncytial virus: apoptosis is an important pathway of virus clearance after experimental infection with bovine respiratory syncytial virus. Am J Pathol (2002) 1.17
Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6. Blood (2009) 1.15
Regulation of cytokine production by virus-specific CD8 T cells in the lungs. J Virol (2008) 1.11
Altered pathogenesis of severe pneumovirus infection in response to combined antiviral and specific immunomodulatory agents. J Virol (2003) 1.08
A role for airway remodeling during respiratory syncytial virus infection. Respir Res (2005) 1.06
Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness. J Virol (2004) 0.96
Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine model. J Virol (2009) 0.90
Treatment with anti-LFA-1 delays the CD8+ cytotoxic-T-lymphocyte response and viral clearance in mice with primary respiratory syncytial virus infection. J Virol (2004) 0.89
Perforin and granzymes work in synergy to mediate cholangiocyte injury in experimental biliary atresia. J Hepatol (2013) 0.88
Granzyme B regulates antiviral CD8+ T cell responses. J Immunol (2011) 0.86
Epitope-specific regulatory CD4 T cells reduce virus-induced illness while preserving CD8 T-cell effector function at the site of infection. J Virol (2010) 0.83
Apoptosis in pneumovirus infection. Viruses (2013) 0.80
A Numerically Subdominant CD8 T Cell Response to Matrix Protein of Respiratory Syncytial Virus Controls Infection with Limited Immunopathology. PLoS Pathog (2016) 0.80
Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity. Paediatr Respir Rev (2015) 0.78
The Fas death factor. Science (1995) 13.81
Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature (1994) 11.22
Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA (1999) 8.07
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature (1994) 5.58
Induction of apoptosis in mature T cells by tumour necrosis factor. Nature (1995) 5.26
Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science (1993) 4.80
Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med (1993) 4.53
Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell (1994) 4.26
CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol (1997) 4.10
Immune function in mice lacking the perforin gene. Proc Natl Acad Sci U S A (1994) 4.06
Primary respiratory syncytial virus infection in mice. J Med Virol (1988) 3.77
Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest (1991) 3.71
Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration. J Exp Med (1995) 3.40
Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med (1988) 3.39
Characterization of early IL-12, IFN-alphabeta, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection. J Immunol (1996) 3.30
Fas and FasL in the homeostatic regulation of immune responses. Immunol Today (1995) 3.24
Respiratory syncytial virus infection in adults. Clin Microbiol Rev (2000) 3.16
The CTL's kiss of death. Cell (1995) 2.80
Perforin: structure and function. Immunol Today (1995) 2.42
Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. J Immunol (1986) 2.13
Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells. Immunology (1987) 2.02
A role for perforin in downregulating T-cell responses during chronic viral infection. J Virol (1999) 1.84
How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol (1998) 1.80
Cell-mediated cytotoxic response to respiratory syncytial virus in infants with bronchiolitis. Lancet (1987) 1.80
Immunological determinants of disease caused by respiratory syncytial virus. Trends Microbiol (1996) 1.76
Fas and the art of lymphocyte maintenance. J Exp Med (1996) 1.65
Fas-based lymphocyte-mediated cytotoxicity against syngeneic activated lymphocytes: a regulatory pathway? Eur J Immunol (1994) 1.58
Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus. J Virol (1997) 1.55
Activation-induced death of mature T cells in the regulation of immune responses. Curr Opin Immunol (1995) 1.48
Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T cells. J Virol (1993) 1.47
Immune-mediated disease pathogenesis in respiratory syncytial virus infection. Immunopharmacology (2000) 1.41
Cytotoxic T lymphocyte control of acute lymphocytic choriomeningitis virus infection: interferon gamma, but not tumour necrosis factor alpha, displays antiviral activity in vivo. J Gen Virol (1989) 1.37
Homeostatic regulation of CD8+ T cells by perforin. Eur J Immunol (1999) 1.29
Respiratory syncytial virus infection in anti-mu-treated mice. J Virol (1991) 1.20
Respiratory syncytial virus infection in C57BL/6 mice: clearance of virus from the lungs with virus-specific cytotoxic T cells. J Virol (1991) 1.20
Induction of CD95 (Fas) and apoptosis in respiratory epithelial cell cultures following respiratory syncytial virus infection. Virology (1999) 1.16
Development of cell-mediated cytotoxic immunity to respiratory syncytial virus in human infants following naturally acquired infection. J Med Virol (1989) 1.08
Fas-dependent CD4+ cytotoxic T-cell-mediated pathogenesis during virus infection. Proc Natl Acad Sci U S A (1996) 1.07
Fas and other cell death signaling pathways. Semin Immunol (1997) 1.04
IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity In vivo. J Immunol (2000) 1.03
Protective Role of TNF-alpha in respiratory syncytial virus infection in vitro and in vivo. Am J Med Sci (1996) 1.02
Perforin-deficient CD8+ T cells: in vivo priming and antigen-specific immunity against Listeria monocytogenes. J Immunol (1999) 0.98
Antiviral effect of TNF-alpha and IFN-gamma secreted from a CD8+ influenza virus-specific CTL clone. Viral Immunol (1993) 0.83
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol (1998) 2.63
Acute pubic osteomyelitis in athletes. Clin Infect Dis (1992) 2.29
Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J Virol (1998) 2.21
Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol (1986) 2.09
Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J Clin Microbiol (1986) 1.79
Opportunistic infections in endogenous Cushing's syndrome. Ann Intern Med (1984) 1.76
Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J Clin Invest (1994) 1.67
Rhodococcus equi--an increasingly recognized opportunistic pathogen. Report of 12 cases and review of 65 cases in the literature. Am J Clin Pathol (1995) 1.66
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine (2010) 1.66
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis (1999) 1.64
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine (2013) 1.56
Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus. J Virol (1997) 1.55
Vaccination with pertussis toxin alters the antibody response to simultaneous respiratory syncytial virus challenge. J Infect Dis (1999) 1.54
Features and outcomes of classic heat stroke. Ann Intern Med (1999) 1.54
Serum vitamin A levels in respiratory syncytial virus infection. J Pediatr (1994) 1.53
Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. J Infect Dis (1988) 1.52
Adult immunization with acellular pertussis vaccine. JAMA (1993) 1.47
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med (1991) 1.43
Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol (1999) 1.42
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine (2001) 1.35
Respiratory syncytial virus infection prolongs methacholine-induced airway hyperresponsiveness in ovalbumin-sensitized mice. J Med Virol (1999) 1.34
A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. Nat Med (2000) 1.26
Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection. J Clin Microbiol (1986) 1.22
RhoA interacts with the fusion glycoprotein of respiratory syncytial virus and facilitates virus-induced syncytium formation. J Virol (1999) 1.14
Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice. Am J Respir Crit Care Med (2000) 1.12
Immune interaction between respiratory syncytial virus infection and allergen sensitization critically depends on timing of challenges. J Infect Dis (2001) 1.12
Myocardial abscess with complete heart block complicating anaerobic infective endocarditis. Br Heart J (1986) 1.11
Respiratory syncytial virus infection does not increase allergen-induced type 2 cytokine production, yet increases airway hyperresponsiveness in mice. J Med Virol (2001) 1.10
A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate. J Immunol Methods (2010) 1.10
Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrob Agents Chemother (2001) 1.08
Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine (1997) 1.06
Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV. J Infect Dis (2000) 1.06
Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol (2012) 1.05
Interleukin-4 diminishes CD8(+) respiratory syncytial virus-specific cytotoxic T-lymphocyte activity in vivo. J Virol (1999) 1.05
Herpes simplex virus infection of the adult lower respiratory tract. Medicine (Baltimore) (1983) 1.05
Human peripheral blood xenografts in the SCID mouse: characterization of immunologic reconstitution. J Infect Dis (1993) 1.04
IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity In vivo. J Immunol (2000) 1.03
Protective Role of TNF-alpha in respiratory syncytial virus infection in vitro and in vivo. Am J Med Sci (1996) 1.02
Interleukin-12 treatment during immunization elicits a T helper cell type 1-like immune response in mice challenged with respiratory syncytial virus and improves vaccine immunogenicity. J Infect Dis (1995) 1.01
Dysphagia associated with an aortic arch anomaly in adults. Am Surg (1986) 1.00
Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J Clin Invest (1993) 0.98
RhoA is activated during respiratory syncytial virus infection. Virology (2001) 0.98
T cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice. J Clin Invest (1997) 0.98
Mycobacterium chelonae: a cause of nodular skin lesions with a proclivity for renal transplant recipients. Am J Med (1989) 0.97
Endocarditis and infections of intravascular devices due to Eikenella corrodens. Am J Med Sci (1986) 0.97
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses (1997) 0.96
Acid-fast bacilli on buffy coat smears in the acquired immunodeficiency syndrome: a lesson from Hansen's bacillus. South Med J (1984) 0.95
Suppression of airway hyperresponsiveness induced by ovalbumin sensitisation and RSV infection with Y-27632, a Rho kinase inhibitor. Thorax (2002) 0.94
A radioreceptor assay for evaluation of the plasma glucocorticoid activity of natural and synthetic steroids in man. J Clin Endocrinol Metab (1975) 0.94
Nonexertional heatstroke. Physiologic management and cooling in 14 patients. Arch Intern Med (1986) 0.92
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses (2000) 0.92
Pseudomonas aeruginosa causing osteomyelitis after puncture wounds of the foot. South Med J (1984) 0.92
Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses (1996) 0.90
Neutralizing antibody responses in Africa green monkeys naturally infected with simian immunodeficiency virus (SIVagm). J Med Primatol (1999) 0.89
Testicular choriocarcinoma metastatic to the skin: an additional case and literature review. Cutis (2001) 0.89
Determinants and kinetics of cytokine expression patterns in lungs of vaccinated mice challenged with respiratory syncytial virus. Vaccine (1997) 0.89
Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network. J Clin Immunol (1992) 0.89
Transepidermal migration of external cardiac pacing wire presenting as a cutaneous nodule. J Am Acad Dermatol (2000) 0.87
Blastomycosis presenting as monoarticular arthritis. The role of synovial fluid cytology. Arthritis Rheum (1985) 0.87
Pertussis toxin sensitization alters the pathogenesis of subsequent respiratory syncytial virus infection. J Infect Dis (2000) 0.86
Respiratory syncytial virus infection enhances the response to laryngeal chemostimulation and inhibits arousal from sleep in young lambs. Acta Paediatr (1996) 0.86
Construction and characterization of recombinant vaccinia viruses co-expressing a respiratory syncytial virus protein and a cytokine. J Gen Virol (2001) 0.84
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network. Clin Exp Immunol (1994) 0.84
Viruses, dendritic cells and the lung. Respir Res (2001) 0.84
Dental soft polymers: plasticizer composite and leachability. Dent Mater (1988) 0.84
Chronic fibrosing mediastinitis and superior vena caval obstruction from blastomycosis. Ann Thorac Surg (1992) 0.83
Response of cutaneous Rosai-Dorfman disease to topical and intralesional steroids. Br J Dermatol (2003) 0.83
Interpreting HIV serodiagnostic test results in the 1990s: social risks of HIV vaccine studies in uninfected volunteers. NIAID AIDS Vaccine Clinical Trials Group. Ann Intern Med (1994) 0.83
Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge. J Infect Dis (1999) 0.82
Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus. J Infect Dis (1999) 0.82
Pericarditis associated with Hemophilus influenzae type B pneumonia and bacteremia in two adults. Chest (1983) 0.82
Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines. J Immunol (1997) 0.82
The clinical superiority of continuous exposure versus short-pulsed carbon dioxide laser exposures for the treatment of pearly penile papules. Dermatol Surg (1999) 0.82
High-level PEEP in severe asthma. N Engl J Med (1983) 0.80
Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network. AIDS Res Hum Retroviruses (1994) 0.80
Human respiratory syncytial virus reduces the number of cells in S-phase and increases GADD153 expression in HEp-2 cells. Acta Virol (2009) 0.80
Ludwig's angina resulting from the infection of an oral malignancy. J Oral Maxillofac Surg (1985) 0.78
Safety and pharmacokinetics of vitamin A therapy for infants with respiratory syncytial virus infections. Antimicrob Agents Chemother (1995) 0.76
Counterfeit calculi. South Med J (1984) 0.76
Vitamin A therapy for respiratory syncytial virus infection. Pediatr Infect Dis J (1997) 0.75
Influence of plasticizer on soft polymer gelation. J Dent Res (1986) 0.75
Hospitalization costs of respiratory syncytial virus infection. Pediatr Infect Dis J (2001) 0.75
Perinatal transmission of human immunodeficiency virus-1 infection and maternal immunization strategies for prevention. Obstet Gynecol (1992) 0.75
Atypical mycobacterial infections. South Med J (1989) 0.75
Clostridial infection of renal cell carcinoma. J Urol (1986) 0.75
The effects of cemented and uncemented endosseous implants. J Prosthet Dent (1979) 0.75
Mucosal denudation of the lips from isotretinoin therapy. Arch Dermatol (1999) 0.75
Gel strength and rate of gelation of soft polymers. Dent Mater (1991) 0.75
Extrapulmonary thoracic disease caused by Blastomyces dermatitidis. Chest (1994) 0.75
Pseudogout presenting with low synovial fluid glucose: identification of crystals by gram stain. Am J Med Sci (1985) 0.75
Detection of bacteremia and fungemia: microscopic examination of peripheral blood smears. Infect Control (1984) 0.75
This is our future. J Mich Dent Assoc (1993) 0.75
Cancer cellulitis. South Med J (1984) 0.75
Pseudotumor of the lung. Am Surg (1985) 0.75